Divide & Conquer

OverviewSuggest Edit

Divide & Conquer is a biotechnology company. It is focused on developing new therapeutics against glioblastoma (grade IV astrocytoma), a particularly lethal form of brain cancer, and other solid tumors with very poor life expectancy.
TypePrivate
Founded2018
Websiteconquer.bio

Latest Updates

Employees (est.) (Jan 2020)1

Key People/Management at Divide & Conquer

David Grainger

David Grainger

Executive Chairman Co-Founder & Director
Miroslav Radman

Miroslav Radman

Co-Founder & Co-Chair of Scientific Advisory Board
Frank Winkler

Frank Winkler

Co-Founder & Co-Chair of Scientific Advisory Board
Show more

Divide & Conquer Financials and Metrics

Summary Metrics

Founding Date

2018

Divide & Conquer total Funding

$12.5 m

Divide & Conquer latest funding size

$12.47 m

Time since last funding

5 months ago

Divide & Conquer investors

Divide & Conquer's latest funding round in September 2019 was reported to be $12.5 m. In total, Divide & Conquer has raised $12.5 m
Show all financial metrics

Divide & Conquer Online and Social Media Presence

Embed Graph

Divide & Conquer Frequently Asked Questions

  • When was Divide & Conquer founded?

    Divide & Conquer was founded in 2018.

  • Who are Divide & Conquer key executives?

    Divide & Conquer's key executives are David Grainger, Miroslav Radman and Frank Winkler.

  • How many employees does Divide & Conquer have?

    Divide & Conquer has 1 employees.

  • Who are Divide & Conquer competitors?

    Competitors of Divide & Conquer include CytomX Therapeutics, Infinity Pharmaceuticals and Paradigm Diagnostics.